ABSTRACT Objective Assess the efficacy and safety of carbetocin, versus oxytocin in the prevention of postpartum hemorrhage in hypertensive women. Study design A randomized clinical trial. Setting Obstetrics and Gynecology Department of Suez Canal University Hospital. Patients One hundred and sixty hypertensive pregnant women who underwent CS. Interventions Patients were randomized to receive either 10 IU oxytocin or 100 μg carbetocin. Primary outcomes included estimated blood loss, blood transfusion, hemoglobin (HB), and hematocrit changes pre- and post-delivery and the use of additional uterotonics. Results The postoperative HB was not different from preoperative HB in the carbetocin group (11.8 ± 1.2 vs. 11.2 ± 1.2 g/dL) while it decreased significantly in the oxytocin group (12.1 ± 3.8 vs. 10.4 ± 1.1 g/dL, p < 0.001). Blood loss was significantly more among the oxytocin group (679.5 ± 200.25 vs. 424.75 ± 182.59 ml) in the carbetocin group (p < 0.001). Nausea, vomiting, and sweating were reported more significantly in oxytocin group patients. Conclusion Carbetocin was more effective than oxytocin in reducing intraoperative and postoperative blood loss.

中文翻译：

---

卡贝缩宫素对比催产素预防择期剖宫产的高血压妇女产后出血

摘要 目的 评估卡贝缩宫素与催产素在预防高血压女性产后出血中的有效性和安全性。研究设计 一项随机临床试验。设置苏伊士运河大学医院妇产科。患者 160 名接受 CS 的高血压孕妇。干预 患者随机接受 10 IU 催产素或 100 μg 卡贝缩宫素。主要结果包括估计的失血量、输血、血红蛋白 (HB) 和分娩前后血细胞比容的变化以及使用额外的宫缩剂。结果卡贝缩宫素组术后HB与术前HB无差异（11.8±1.2 vs. 11.2±1.2 g/dL），而催产素组显着降低（12.1±3.8 vs. 10.4±1.1 g/dL，p < 0.001）。卡贝缩宫素组中催产素组的失血量明显更多（679.5 ± 200.25 与 424.75 ± 182.59 ml）（p < 0.001）。在催产素组患者中报告的恶心、呕吐和出汗更为显着。结论卡贝缩宫素在减少术中和术后失血量方面优于催产素。